Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge | NEJM – nejm.org

After emergency use of the mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine was authorized, the observer-blinded, pivotal Coronavirus Efficacy (COVE) trial was amended on December 23, 2020, to include an open-label phase in…

Click here to view the original article.